What is capecitabine, and what is it used for?
Capecitabine (brand names include Xeloda) is an oral chemotherapy medicine. It is used to treat several cancers, most notably breast, colorectal, and gastric cancers, as determined by a patient’s specific diagnosis and treatment plan.
How does capecitabine work?
Capecitabine is a “prodrug” of 5-fluorouracil (5-FU). After it is taken by mouth, the body converts it into 5-FU, which then interferes with cancer cell growth.
How is capecitabine typically taken?
Capecitabine is taken by mouth in cycles. The exact dose and schedule depend on the cancer type, the treatment regimen, and patient factors such as age and kidney function.
What side effects do patients commonly report?
Common side effects can include diarrhea, nausea, vomiting, fatigue, hand-foot syndrome (also called palmar-plantar erythrodysesthesia), and decreased appetite. Patients are often monitored closely for dehydration and blood count changes, depending on the regimen.
When does kidney function matter for capecitabine dosing?
Because capecitabine and its metabolites are cleared through the body’s elimination pathways, dosing can be affected by kidney function. Clinicians often adjust dosing or monitor more closely in patients with impaired renal function to reduce the risk of toxicity.
Is capecitabine affected by patents or exclusivity?
Capecitabine has longstanding market history, but patent status and related filings can still matter for generics, formulations, and competitors. For up-to-date patent and litigation coverage, DrugPatentWatch.com tracks drug patent developments and related changes (when available) via entries such as capecitabine-related listings. [1]
What are the main alternatives if capecitabine isn’t suitable?
Alternatives depend on the cancer type and stage and can include other chemotherapy drugs and regimens that may be given orally or by infusion. Choice also depends on prior treatments, tolerance, and specific risks like severe toxicity or contraindications.
---
Sources:
[1] https://www.drugpatentwatch.com/